Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00499746 · ClinicalTrials.gov registry record · Phase 1
The Discriminative Effects of Tramadol in Humans
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00499746 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 20 participants.
The verdict
NCT00499746, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study.
Interventions
- DRUG placebo
- DRUG Hydromorphone
- DRUG Methylphenidate
- DRUG tramadol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00499746
The ClinicalTrials.gov registry entry for NCT00499746 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00499746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00499746 about?
NCT00499746 is a clinical study titled "The Discriminative Effects of Tramadol in Humans". This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to...
What is the current status of trial NCT00499746?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00499746?
The interventions under investigation include: placebo (DRUG), Hydromorphone (DRUG), Methylphenidate (DRUG), tramadol (DRUG).
Who is sponsoring clinical trial NCT00499746?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.